Management Team

Clinical Microbiomics brings together a team of highly trained molecular biologists and bioinformatics scientists with years of experience in designing and implementing successful microbiome studies. In addition to the operational backbone, we draw on a global network of exclusive advisors offering to support the trial design process, data interpretation and support strategic decisions related to use of microbiome analysis in your organization.

Martin Andreas Santini, PhD (Chief Executive Officer) has a background as a human biologist and holds a PhD in Health and Medical Sciences from the University of Copenhagen and Harvard Medical School. He has worked with molecular technologies in clinical microbiology at Copenhagen University Hospital Rigshospitalet and the Health Protection Agency in the UK. Martin is well-versed in strategy and business development through working as a management consultant in Bain & Company, mainly within the pharma and biotech area. Extensive experience within the private equity sector positions him well to understand market developments and opportunities. Prior to joining Clinical Microbiomics, Martin worked at the industrial biotech company Novozymes as a part of the R&D Leadership Team.

H. Bjørn Nielsen, PhD (Chief Scientific Officer) holds a PhD in Systems Biology from the Technical University of Denmark (DTU), an MSc in Biology from the University of Copenhagen, and a leader education from Harvard Business School. Prior to joining Clinical Microbiomics, Bjørn was leading the Microbiome Systems Biology group at DTU. Bjørn has been a frontrunner in microbiome research for the last 10 years and brings extensive experience in analysing, integrating and managing diverse types of data. Bjørn’s research has mainly focused on the ecology and temporal dynamics of the human gut microbiome and its role in disease. This has been pursued by integration and mining of shotgun metagenomics, metatranscriptomics, metabolomics and patient data, and lead to the development of several important analysis methods and concepts. Bjørn has authored 16 high-impact papers published in Nature and Cell journals, and his publications currently receive more than 2800 citations per year.



Jens Roat Kultima, PhD (Director of Bioinformatics) holds a BSc and. MSc in Bioinformatics from Uppsala University and completed his PhD in metagenomics under the supervision of Dr. Peer Bork at the European Molecular Biology Laboratory in Heidelberg, Germany. During his PhD, he developed one of the first end-to-end processing pipelines for Illumina metagenomics data and played an integral role in the processing and analysis of data for the largest microbial human gut gene catalog and the detection of early stage colorectal cancer using a set of microbial marker species. Prior to joining CM, Jens has also developed metagenomic analysis methods applied to human clinical trials at Janssen Human Microbiome Institute in Boston, U.S. He has 12+ years programming experience, in addition to having conducted research at MIT, Harvard, and institutions in Brazil, China, New Zealand and Scotland.

Aron Charles Eklund, PhD (Director of Bioinformatics) holds a PhD in Systems Biology from the Technical University of Denmark. Aron has 16 years experience in bioinformatics and was most recently an Associate Professor at the Technical University of Denmark, where his research focused on development and application of cutting-edge genomics and computational methods for cancer diagnosis, personalized treatment, and target discovery for immunotherapy. His works, including 43 scientific articles and 4 patent applications, have been cited over 10,000 times.

Nikolaj Sørensen, PhD (Director of Scientific Operations) has a PhD in microbial ecology from the Centre of Excellence, Center for Macroecology, Evolution and Climate at the University of Copenhagen. He combines a strong ecological background with extensive knowledge on molecular analyses of microorganisms to gain insight into the microbial world. Nikolaj has a holistic approach to microbiomics, both from a methodological and analytical perspective: results can only be fully understood with deep knowledge of the methods used and the microbial communities are best seen as a whole that is more than the sum of its parts.

Jacob Bak Holm, PhD (Director of Scientific Operations) holds a PhD in gut microbiota from University of Copenhagen, and a MSc in Molecular Biomedicine from University of Copenhagen. Prior to joining Clinical Microbiomics, Jacob was working as postdoc in Laboratory of Genomics and Molecular Biomedicine at University of Copenhagen under professor Karsten Kristiansen. Jacob has been in charge of/involved in a broad variety of animal and human studies focusing on how diet, pathogens, diseases, prebiotics and probiotics modulate the gut microbiota and what potential functional consequences this can have for the host. Jacob holds a FELASA C license and is experienced in working with mice as a laboratory animal model for gut microbiota and metabolism studies. Jacob possesses previous unique hands-on experience with collection and anlyzing challenging samples ranging from highly controlled human and animal trials to catching and sampling of wild vampire bats in the jungles of Belize and chickens in the remote areas of Africa. In addition to his experience in performing the studies he is also skilled in analyzing the gut microbiota data.

Klaus Gamst Hansen, MSc (Director of Sales & Business Development) has a unique profile combining a master’s degree in medical biology and communication studies and professional experience from competitive intelligence within Novo Nordisk, health communication in The Danish Cancer Society, medical research at Hvidovre Hospital and commercialization and start-up analytical experience from Danish consultancy company TTO. Klaus is inspired by the interface between research and business and thrives in creating professional connections and relationships. Klaus combines great communicative and interpersonal skills, a broad professional background and working experience from different companies and institutions in the field of medical research and business development.